Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Farmers Insurance
Queensland Health
McKesson
Mallinckrodt
US Army
AstraZeneca
Chubb
Covington

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,362,178

« Back to Dashboard

Summary for Patent: 6,362,178
Title: 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Abstract:The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
Inventor(s): Niewohner; Ulrich (Wermelskirchen, DE), Es-Sayed; Mazen (Langenfeld, DE), Haning; Helmut (Wuppertal, DE), Schenke; Thomas (Gladbach, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Bischoff; Erwin (Wuppertal, DE), Perzborn; Elisabeth (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Serno; Peter (Gladbach, DE), Nowakowski; Marc (Wuppertal, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:09/554,162
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 6,362,178

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ERECTILE DYSFUNCTION ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-003 Aug 19, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ERECTILE DYSFUNCTION ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-001 Aug 19, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ERECTILE DYSFUNCTION ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-002 Aug 19, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ERECTILE DYSFUNCTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,362,178

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 50 085Nov 12, 1997
Germany198 12 462Mar 23, 1998
Germany198 40 289Sep 04, 1998
PCT Information
PCT FiledOctober 31, 1998PCT Application Number:PCT/EP98/06910
PCT Publication Date:May 20, 1999PCT Publication Number: WO99/24433

Non-Orange Book US Patents Family Members for Patent 6,362,178

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,122,540 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Sign Up
7,314,871 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension ➤ Sign Up
7,696,206 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Sign Up
6,566,360 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Chubb
Fuji
Boehringer Ingelheim
QuintilesIMS
AstraZeneca
Express Scripts
Julphar
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.